---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Immune checkpoint inhibitors"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Immune checkpoint inhibitors. Topics: Guideline recommendation on combination immunotherapy and patient selection; Guideline summary of anti-PD-1 monotherapy outcomes in uveal melanoma; Guideline summary of phase 2 trials of nivolumab plus ipilimumab; Indirect comparison of tebentafusp, nivolumab plus ipilimumab, and pembrolizumab in first-line disease: guideline summary; 10 further topics. 14 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/immune-checkpoint-inhibitors"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Immune checkpoint inhibitors

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Immune Checkpoint Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

### Guideline recommendation on combination immunotherapy and patient selection

> “Given the lack of a clear survival advantage in metastatic UM associated with nivolumab–ipilimumab versus pembrolizumab and the increased toxicity associated with the former, only selected patients fit enough for the combination and with predominant extrahepatic disease should be considered for the combination immunotherapy.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.2-2"></a>

### Guideline summary of anti-PD-1 monotherapy outcomes in uveal melanoma

> “Patients with metastatic UM have been excluded from most trials evaluating ICIs in cutaneous melanoma.”
> “Although the safety profile of PD-1 inhibitors was better in UM compared with cutaneous melanoma, efficacy was comparatively disappointing, showing <5% ORR, median PFS of 3 months and 1-year OS ∼50%, likely due to low tumour mutational burden, poor antigen processing and presentation and the immune-suppressive tumour microenvironment in UM.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.2-3"></a>

### Guideline summary of phase 2 trials of nivolumab plus ipilimumab

> “In two phase II studies in 52 and 33 patients, respectively, nivolumab–ipilimumab was associated with ORR of 11% and 18%, median PFS of 3 and 5.5 months and median OS of 12 and 19 months, respectively, after a median follow-up of ∼13 months.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.2-4"></a>

### Indirect comparison of tebentafusp, nivolumab plus ipilimumab, and pembrolizumab in first-line disease: guideline summary

> “In the absence of randomised comparative studies, indirect comparisons of ICIs with tebentafusp in first-line metastatic UM have been conducted.”
> “A propensity score analysis of two studies showed an OS benefit for tebentafusp versus nivolumab–ipilimumab (1-year OS rate of 73% versus 50%, respectively), independent of HLA status, and no significant difference in survival between pembrolizumab and nivolumab–ipilimumab (median OS and 1-year OS rate of 16.9 months and 60% versus 14.2 months and 52%, respectively).”
> “Toxicity rates were higher with nivolumab–ipilimumab compared with pembrolizumab (23% versus 2%-5% treatment-related discontinuations and two versus no treatment-related deaths).”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.2-5"></a>

### First-line nivolumab plus ipilimumab: single-arm phase 2 trial of the Spanish Multidisciplinary Melanoma Group, 52 participants

> “This was a single-arm, phase II trial led by the Spanish Multidisciplinary Melanoma Group (GEM) on nivo plus ipi for systemic treatment-naïve patients of age > 18 years, with histologically confirmed MUM, Eastern Cooperative Oncology Group-PS 0/1, and confirmed progressive metastatic disease (M1).”
> “Nivo (1 mg/kg once every 3 weeks) and ipi (3 mg/kg once every 3 weeks) were administered during four inductions, followed by nivo (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.”
> “A total of 52 patients with a median age of 59 years (range, 26-84 years) were enrolled.”
> “The primary end point was 12-month OS, which was 51.9% (95% CI, 38.3 to 65.5).”
> “The median OS and PFS were 12.7 months and 3.0 months, respectively.”
> “Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile.”

Source: [Piulats et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33417511/)

<a id="topic-2.2.2.1.2-6"></a>

### Nivolumab plus ipilimumab: single-arm phase 2 trial of 35 participants

> “This single-arm phase II study of nivolumab and ipilimumab in patients with metastatic uveal melanoma demonstrated an overall response rate (ORR) of 18%, a median progression-free survival of 5.5 months, and a median overall survival of 19.1 months.”
> “Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy.”
> “The ORR was 18%, including one confirmed complete response and five confirmed partial responses.”
> “For the 35 patients included in the study, the median OS was 19.1 months (95% CI, 9.6 months to NR), and the 1-year OS was 56% (95% CI, 38% to 71%).”
> “The ORR in the 31 evaluable patients who were checkpoint naïve was 19%.”

Source: [Pelster et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8257877/)

<a id="topic-2.2.2.1.2-7"></a>

### Nivolumab plus ipilimumab in practice: multicenter retrospective study of 89 participants

> “We conducted a retrospective analysis of patients with metastatic UM (mUM) who received treatment with ipilimumab plus nivolumab across 14 academic medical centers.”
> “89 eligible patients were identified.”
> “Overall response rate was 11.6%.”
> “Median OS from treatment initiation was 15 months and median PFS was 2.7 months.”

Source: [Najjar et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7319717/)

<a id="topic-2.2.2.1.2-8"></a>

### Ipilimumab plus a PD-1 inhibitor at 16 German skin cancer centers: 64 participants

> “The clinical data of 64 patients from 16 German skin cancer centers who met the inclusion criteria were investigated.”
> “The best overall response rate to combined checkpoint blockade was 15.6% with 3.1 and 12.5% complete and partial response, respectively.”
> “The median PFS was 3.0 months (95% CI 2.4–3.6).”
> “The median OS was estimated to 16.1 months (95% CI 12.9–19.3).”

Source: [Heppt et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6854774/)

<a id="topic-2.2.2.1.2-9"></a>

### First-line pembrolizumab: prospective observational cohort of 17 participants

> “In this prospective observational cohort single arm study, we investigated efficacy and safety of Pembrolizumab as first-line therapy for mUM.”
> “Seventeen patients were enrolled.”
> “Two patients achieved partial response (11.7%), 6 a disease stabilization (35.3%), whereas 9 (53%) had a progression.”
> “Toxicity was mild, without grade 3–4 side effects.”

Source: [Rossi et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6584707/)

<a id="topic-2.2.2.1.2-10"></a>

### PD-1 or PD-L1 antibody monotherapy: multicenter retrospective series of 56 participants

> “Safety and clinical efficacy outcomes including best overall response (BOR), progression-free survival (PFS), overall survival (OS) were determined retrospectively.”
> “we report clinical outcomes in a larger series of 56 patients treated at nine institutions with PD-1 (pembrolizumab or nivolumab) or PD-L1 (atezolizumab) antibodies.”
> “Objective tumor responses were observed in two patients for an overall response rate of 3.6% (95% CI 1.8-22.5%).”
> “The median PFS was 2.6 months (95% CI 2.4-2.8 months) and the median OS was 7.6 months (95% CI 0.7-14.6 months).”

Source: [Algazi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767160/)

<a id="topic-2.2.2.1.2-11"></a>

### PD-1 inhibitor monotherapy at 20 German skin cancer centres: 86 participants

> “Patients with metastatic UM treated with either PD-1 inhibitor monotherapy or combined PD-1 inhibitor and ipilimumab (an anti-CTLA-4 monoclonal antibody) were included from 20 German skin cancer centres.”
> “Eighty-six patients were treated with PD-1 inhibitors only (n = 54 for pembrolizumab, n = 32 for nivolumab) with a centrally confirmed response rate of 4.7%.”
> “Median OS was 14 months for pembrolizumab-treated and 10 months for nivolumab-treated patients (p = 0.765).”

Source: [Heppt et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28648699/)

<a id="topic-2.2.2.1.2-12"></a>

### Ipilimumab monotherapy: phase 2 DeCOG trial in pretreated and treatment-naïve participants

> “We performed an open-label, multicenter, single-arm phase II clinical trial (DeCOG-trial) to further evaluate the efficacy and safety of 3mg/kg ipilimumab in treatment-naïve and pretreated patients with advanced UM seen in daily routine in interdisciplinary skin cancer units in Germany.”
> “Forty five pretreated (85%) and eight treatment-naïve (15%) patients received at least one dose of ipilimumab.”
> “Median OS was 6.8 months (95% CI 3.7–8.1), median progression-free survival 2.8 months (95% CI 2.5–2.9).”
> “Sixteen patients had stable disease (47%), none experienced partial or complete response.”
> “Treatment-related AEs were observed in 35 patients (66%), including 19 grade 3–4 events (36%).”

Source: [Zimmer et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4356548/)

<a id="topic-2.2.2.1.2-13"></a>

### Ipilimumab monotherapy after prior treatment: expanded access program of 82 assessable participants

> “Pre-treated patients with advanced uveal melanoma received ipilimumab 3 mg/kg through an expanded access programme, every 3 weeks for four doses.”
> “Among 82 assessable patients, 4 (5%) had an immune-related objective response and 24 (29%) had immune-related stable disease lasting ≥3 months for an immune-related disease control rate of 34%.”
> “With a median follow-up of 5.6 months, median overall survival (OS) was 6.0 months and median progression-free survival (PFS) was 3.6 months.”

Source: [Maio et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24067719/)

<a id="topic-2.2.2.1.2-14"></a>

### Meta-analysis of response and survival by checkpoint inhibitor class

> “Pooled ORR was 9.2% overall (95% CI 7.2-11.8) [4.1% for anti-CTLA4 (95% CI 2.1-7.7), 7.1% for anti-PD(L)1 (95% CI 4.5-10.9) and 13.5% for anti-CTLA4 plus anti-PD1 (95% CI 10.0-18.0)].”
> “Median OS was 11.5 months overall (95% CI 9.5-13.8) [8.0 months for anti-CTLA4 (95% CI 5.5-9.9), 11.7 months for anti-PD(L)1 (95% CI 9.0-14.0) and 16.0 months for ipilimumab plus anti-PD1 (95% CI 11.5-17.7) ( P < 0.001)].”
> “Median PFS was 3.0 months overall (95% CI 2.9-3.1).”

Source: [Pham et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37199712/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
